Results 71 to 80 of about 307,974 (304)

Daganatos sejtek rezisztenciáját gátló vegyületek fejlesztése = Development of compounds targeting multidrug resistant cancer [PDF]

, 2009
A korszerű daganatellenes terápia jelentős sikerei ellenére a kemoterápiával szemben fellépő rezisztencia (multidrog rezisztencia, MDR) továbbra is megoldásra váró klinikai kihívás.
Szakács, Gergely
core  

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]

, 2018
Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard, Garrido, Pilar, Goldman, Jonathan W., Gutierrez, Martin, Hossain, Anwar, Jalal, Shadia, John, William J., Johnston, Erica L., Kambhampati, Siva Rama Prasad, Kelly, Karen, Kim, Edward S., Mahadevan, Daruka, Paz-Ares, Luis G., Provencio, Mariano, Schaefer, Eric, Shaheen, Monte, Turner, P. Kellie   +16 more
core   +2 more sources

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Application of pharmacogenomics and bioinformatics to exemplify the utility of human ex vivo organoculture models in the field of precision medicine [PDF]

, 2019
Here we describe a collaboration between industry, the National Health Service (NHS) and academia that sought to demonstrate how early understanding of both pharmacology and genomics can improve strategies for the development of precision medicines ...
A Cilli, AA Agyeman, AE Tilley, AL Chokas, AV Biankin, C-H Chou, Carolyn Low, Colin N. A. Palmer, D Cook, David C. Bunton, David Mallinson, E Arif, Elaine M. Gourlay, Erika Cecchin, G Faura Tellez, Graeme Macluskie, H Yang, Hannah Child, J Milara, J-R Yu, Jane Hair, K Linhart, Karen Cowan, Linda Cheyne, M Zanoni, Marian McNeil, Max Bylesjo, ME Ezzie, Michael Finch, MR Trusheim, NJ Schork, PA André, Pamela Brankin, RC Gentleman, S Purcell, Sarah Lynagh, SI Rennard, SJ Mandrekar, SM Paul, T Yang, W Asghar, WE Johnson, Y Chen   +42 more
core   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Nanocrown electrodes for parallel and robust intracellular recording of cardiomyocytes

Nature Communications, 2022
Nanoelectrodes for measuring intracellular action potentials suffer from issues with success rate, signal strength and fabrication. Here, the authors report on a scalable technique which creates robust nanocrown electrodes with high success rates by ...
Zeinab Jahed, Yang Yang, Ching-Ting Tsai, Ethan P. Foster, Allister F. McGuire, Huaxiao Yang, Aofei Liu, Csaba Forro, Zen Yan, Xin Jiang, Ming-Tao Zhao, Wei Zhang, Xiao Li, Thomas Li, Annalisa Pawlosky, Joseph C. Wu, Bianxiao Cui   +16 more
doaj   +1 more source

Preclinical discovery of duloxetine for the treatment of depression [PDF]

, 2012
Introduction: Affective disorders, including major depressive disorder (MDD), are among the most severely disabling mental disorders, and in many cases areIntroduction: Affective disorders, including major depressive disorder (MDD), are among the most ...
Berrocoso Domínguez, Esther María, Elorza, Julián, Micó Segura, Juan Antonio, Perez-Caballero, Laura, Torres-Sanchez, Sonia   +4 more
core   +2 more sources

Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing

Oncology Letters, 2016
The established urinary antibiotic nitroxoline has recently regained considerable attention, due to its potent activities in inhibiting angiogenesis, inducing apoptosis and blocking cancer cell invasion. These features make nitroxoline an excellent candidate for anticancer drug repurposing.
ZHANG, QI, WANG, SHANSHAN, YANG, DEXUAN, PAN, KEVIN, LI, LINNA, YUAN, SHOUJUN   +5 more
openaire   +3 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source